Balance trial data support olezarsen in familial chylomicronaemia syndrome

Olezarsen 80 mg every four weeks significantly reduces triglycerides (TG) in patients with genetically confirmed familial chylomicronaemia syndrome (FCS), according to data from the Phase 3 Balance trial,¹ presented at ACC.24 and published simultaneously in the New England Journal of Medicine.² Effects on TG seen with the GalNAc3-conjugated antisense oligonucleotide (ASO) targeting apoC-III mRNA were sustained through six and 12 months.